Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 4/20 | 0.51 |
| ▸ | TAS1R1 | Q7RTX1 | 4/20 | 0.51 |
| ▸ | TAS1R2 | Q8TE23 | 3/20 | 0.51 |
| ▸ | WDR5 | P61964 | 1/20 | 0.45 |
| ▸ | RORC | P51449 | 10/20 | 0.44 |
| ▸ | TYK2 | P29597 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2818919 | 1.00 | TAS1R3 (0.51) | TAS1R3TAS1R1TAS1R2WDR5RORC | |
| SCHEMBL2818817 | 0.92 | TAS1R3 (0.59) | TAS1R3TAS1R1TAS1R2PDE4APDE4B | |
| SCHEMBL2818813 | 0.92 | TAS1R3 (0.59) | TAS1R3TAS1R1TAS1R2PDE4APDE4B | |
| SCHEMBL2819195 | 0.89 | TAS1R3 (0.48) | TAS1R3TAS1R1TAS1R2WDR5TYK2 | |
| SCHEMBL2819193 | 0.89 | TAS1R3 (0.48) | TAS1R3TAS1R1TAS1R2WDR5TYK2 | |
| SCHEMBL2820261 | 0.89 | WDR5 (0.45) | TAS1R3TAS1R1TAS1R2WDR5RORC | |
| SCHEMBL2820264 | 0.89 | WDR5 (0.45) | TAS1R3TAS1R1TAS1R2WDR5RORC | |
| SCHEMBL785761 | 0.86 | TAS1R3 (0.51) | TAS1R3TAS1R1TAS1R2RORCPDE4A | |
| SCHEMBL785760 | 0.86 | TAS1R3 (0.51) | TAS1R3TAS1R1TAS1R2RORCPDE4A | |
| SCHEMBL785747 | 0.86 | TAS1R3 (0.47) | TAS1R3TAS1R1TAS1R2WDR5TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130231327-A1 | Substituted Spiro-Amide Compounds | GRUENENTHAL GMBH (DE) | 2013-09-05 | — | — | US | disclosed |
| US-8455475-B2 | Substituted spiro-amide compounds | GRUENENTHAL GMBH (DE) | 2013-06-04 | — | — | US | disclosed |
| US-20100249095-A1 | Substituted Spiro-amide Compounds | GRUENENTHAL GMBH (DE) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231327-A1 | Substituted Spiro-Amide Compounds | BDKRB1, BDKRB2, REN | TAS1R3 339/4885TAS1R1 107/4885TAS1R2 282/4885 |
| US-20100249095-A1 | Substituted Spiro-amide Compounds | BDKRB1, BDKRB2, REN | TAS1R3 339/4885TAS1R1 107/4885TAS1R2 282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.